Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Tolerability of 2 Formulations of LY3502970 in Healthy Participants
NCT05341089Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of orforglipron in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration at Day 35, Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours and 1 more. Started May 2022; status: completed.
02
Drugs
orforglipron
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05341089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341089.